Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction

Annals of Pharmacotherapy

Volumn 35, Issue 4, 2001, Pages 496-500

  Metz, C A ^a   Lucas, K H ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Hypercholesterolemia; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FENOFIBRATE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; SIMVASTATIN; STATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0035060092     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10164     Document Type: Article

References (24)

1. Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease
2. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
3. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
4. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham study
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4s)
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
8. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines
9. Inhibition of cholesterol synthesis by mevinolin stimulates low-density lipoprotein receptor activity in human monocyte-derived macrophages
10. Drug treatment of lipid disorders
11. Statin trials and goals of cholesterol-lowering therapy
12. Use of lipid lowering drugs for primary prevention of coronary heart disease: Meta-analysis of randomized trials
13. The efficacy of extended-interval dosing of omeprazole in keeping gastroesophageal reflux disease patients symptom free
14. Alternate-day dosing of aspirin in atrial fibrillation
15. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study
16. A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients
17. Effect of lovastatin administered every other day on serum low-density lipoprotein cholesterol >160 mg/dl
18. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge
19. The use of alternate-day lovastatin in hypercholesterolemic men
20. A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia
21. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia
22. Efficacy of alternate day dosing versus every day dosing with atorvastatin
23. Evaluation of three methods of administering atorvastatin